Highest-materiality recent filing
Boundless Bio to merge with Serapha; Serapha equityholders to own ~96%
Pre-merger Serapha equityholders to own ~96.31% of combined company; Boundless Bio holders ~3.69% on fully diluted basis.
Boundless Bio Q1 2026 net loss $13.6M; cash $92.8M provides runway into H2 2028
Cash, cash equivalents, and short-term investments $92.8M as of March 31, 2026.
Boundless Bio terminates 80,168 sq ft San Diego lease; pays $10M, forfeits $0.5M deposit
Lease originally set to expire Oct 2034; terminated effective May 31, 2026.
Net loss of $12.9M for Q4 2025 and $58.2M for FY2025, vs $16.4M and $65.4M in same periods of 2024.
Boundless Bio Q2 net loss $15.7M; cash $127.1M funds operations into H1 2028
Net loss $15.7M in Q2 2025 versus $17.0M in Q2 2024; R&D expenses fell to $12.2M from $14.7M.
Boundless Bio restructures pipeline, cuts workforce 33%, discontinues BBI-355 monotherapy
Workforce reduction of ~1/3; expects $1.2M one-time costs, substantially completed in Q2 2025.
Boundless Bio reports Q1 2025 net loss $15.8M; $138.3M cash; BBI-355 data due H2 2025
Cash, cash equivalents, and short-term investments totaled $138.3M as of March 31, 2025, providing runway into 2027.
Boundless Bio Q4 & FY 2024 net loss $65.4M; cash $152.1M; BBI-355 data expected H2 2025
Net loss $16.4M in Q4 2024, full year $65.4M (vs $49.4M in 2023); R&D spend rose to $55.3M.
Boundless Bio stops BBI-825 trial, CMO and CBO depart; cash runway extends to 2027
BBI-825 Phase 1/2 STARMAP trial discontinued due to lack of dose-proportional PK, increased development costs, and competitive landscape changes.
Boundless Bio CFO Jami Rubin steps down; David Hinkle named principal financial officer
Jami Rubin resigned as CFO and Treasurer effective October 11, 2024.
Boundless Bio Q2 net loss $17M; delays BBI-355 combo data to H2 2025
Net loss of $17.0M for Q2 2024 vs $12.4M in Q2 2023; R&D expense $14.7M, G&A $4.7M.
Boundless Bio Q1 net loss $15.4M; cash $105M; IPO adds $100M; BBI-825 trial dosed
Net loss $15.4M in Q1 2024 vs $11.7M in Q1 2023; R&D expenses $13.1M vs $9.5M.
Boundless Bio completes IPO of 6.25M shares at $16.00, raising $100M gross
IPO closed April 2, 2024; 6,250,000 shares sold at $16.00 per share.
effective July 1, 2026, Zachary D. Hornby will cease his role as President and Chief Executive Officer, and as a member of the board of directors of Boundless Bio.
effective July 1, 2026, Jessica Oien, Boundless Bio’s Chief Legal Officer and Corporate Secretary, was appointed to serve as Boundless Bio’s President and "principal executive officer," in addition to maintaining her current responsibilities as Chief Legal Officer and Corporate Secretary.
effective July 1, 2026, Christian Hassig, Ph.D., will cease his role as Boundless Bio’s Chief Scientific Officer
On October 14, 2024, Boundless Bio, Inc. (the “Company”) announced that Jami Rubin, the Company’s Chief Financial Officer and Treasurer, stepped down from her role with the Company.
As of the Effective Date, David Hinkle, the Company’s Senior Vice President, Finance & Controller, was appointed to also serve as the Company’s Treasurer, principal financial officer, and principal accounting officer.
Max materiality 0.90 · Median 0.60 · Most common event earnings